Koning Health Announces Series C Raise Through Strategic Partnership with Sage Tap Poder
Sage Tap Poder's SPV (special purpose vehicle) will directly invest in Koning, supporting the company's next phase of growth as it scales the rollout of the Koning Vera Breast CT (Koning Vera)—the first and only FDA-approved 3D breast imaging system for diagnostic use that delivers high-resolution images without compression or discomfort.
"This Series C round marks a major milestone in our mission to transform breast imaging and empower women with a more accurate, comfortable, and accessible alternative to traditional mammography," said Matthew Stack, CFO of Koning. "Partnering with Sage Tap Poder allows us to bring a broader base of accredited investors into the Koning family at a pivotal time in our commercial expansion."
The funding will accelerate deployment of the Koning Vera in clinics and hospitals across the US, drive reimbursement strategy and adoption among radiologists, and fuel ongoing innovation in 3D imaging technology.
Koning's unique approach replaces the decades-old standard of painful breast compression with a fast, comfortable, and patient-friendly scan that captures a full 360-degree view of breast tissue in 7 seconds per breast—ideal for dense tissue, calcification detection, and routine imaging.
"We're proud to support a company that's redefining women's health through breakthrough imaging technology," said Kirk Honour, Managing Partner at Sage Tap Poder. "This opportunity gives accredited investors the chance to invest in a category-defining medical device company with strong commercial traction and a clear path to scale."
About Koning Health
About Koning: Koning is a global Health Technology company focused on improving the breast imaging industry with its patented Koning Vera Breast CT. Koning's vision is to create a revolution in medical imaging through advanced computed tomography technology that dramatically improves the way clinicians visualize and evaluate breast tissue. The Koning Vera is expected to optimize early disease detection, diagnosis, and intervention by the clinician. For more information, please visit Koning's website.
Accredited investors interested in participating in the offering can contact Kirk Honour at kirk.honour@stpcm.com or 888-558-5228 x803 to learn more about the opportunity.
View original content to download multimedia:https://www.prnewswire.com/news-releases/koning-health-announces-series-c-raise-through-strategic-partnership-with-sage-tap-poder-302463444.html
SOURCE KONING CORPORATION
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 days ago
- Business Wire
Bolt Projects Announces $4.25 Million Private Placement
BERKELEY, Calif.--(BUSINESS WIRE)--Bolt Projects Holdings, Inc. (Nasdaq: BSLK) ('Bolt Projects' or the 'Company'), a developer of biomaterials for the beauty and personal care industry, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 913,979 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.65 per share of common stock (or per pre-funded warrant in lieu thereof, less the nominal exercise price of $0.0001 per share) in a private placement priced at-the-market under Nasdaq rules. The private placement is expected to close on or about August 15, 2025, subject to the satisfaction of customary closing conditions. Bolt Projects Announces $4.25 Million Private Placement; Priced At-The-Market Under Nasdaq Rules Share Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $4.25 million, prior to deducting placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes. The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act'), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the pre-funded warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities issued in the private placement and shares of common stock underlying the pre-funded warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with investors, the Company has agreed to file a resale registration statement covering the securities described above. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Bolt Projects Holdings Bolt Projects develops and produces innovative biomaterials for the beauty and personal care industry. The Company is built on biomaterials platforms that aim to disrupt and transform high-volume consumer goods industries. Bolt Projects is a pioneer in the consumer biomaterials space. The Company's Vegan Silk Technology Platform produces b-silk and other offerings for the beauty and personal care industry that are fully vegan and biodegradable. These versatile ingredients have been on the market since 2019. Its intellectual property portfolio is anchored by 77 granted patents and 118 pending patent applications. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). All statements other than statements of historical facts contained in this communication, including, without limitation, statements regarding: statements related to the completion of the offering, the satisfaction of customary closing conditions related to the offering, and the intended use of proceeds therefrom. In some cases, you can identify forward-looking statements by terminology such as 'anticipate,' 'believe,' 'budget,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'will' or the negatives of these terms or variations of them or similar terminology although not all forward-looking statements contain these words. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: market and other conditions, substantial doubt as to the Company's ability to continue as a going concern; the Company's history of net losses and negative cash flows; the Company's ability to generate sufficient cash to service its debt; the Company's ability to meet the continued listing requirements of Nasdaq and remain listed on a national stock exchange; the Company's ability to execute its business plan and adequately control its expenses or raise additional capital on favorable terms, if at all; the Company's dependence on sales of b-silk™ and xl-silk™ products from its Vegan Silk Technology Platform; the Company's reliance on a single or limited manufacturing partners and manufacturing facilities; reliance on manufacturing partners in regions that could be impacted by U.S. trade policy, including renegotiating or terminating existing trade agreements and leveraging tariffs; costs of and availability for its Vegan technology Platform products that are out of the Company's control; the Company's reliance on a single manufacturing partner and manufacturing facility for the production of its Vegan Silk Technology Platform product; pricing and availability for the Company's Vegan Silk Technology Platform products; market acceptance of from consumer product companies; the Company's ability to protect adequately its patents and other intellectual property assets; government regulations and private party actions relating to the marketing and advertising of cosmetic products that include the Company's Vegan Silk Technology Platform products or other products the Company develops; and the other risks and uncertainties discussed under the caption 'Risk Factors' included in the Company's Annual Report on Form 10-K for the fiscal year ended, December 31, 2024, as such factors may be updated from time to time in its other filings with the SEC, and accessible on the SEC's website at and the Investors section of the Company's website at www. The Company cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. The Company undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
Business Insider
12-08-2025
- Business Insider
Circle Internet (CRCL) Is About to Report Q2 Earnings Today. Here Is What to Expect
Circle Internet Group (CRCL), the issuer of the USDC stablecoin, is scheduled to report its results for the second quarter of 2025 before the market opens on Tuesday, August 12. This will be its first earnings release since going public in June. CRCL stock has surged about 413% to $159.03 from its IPO price of $31, fueled by optimism over the GENIUS Act, which sets rules for stablecoins. Nevertheless, rising competition in the crypto space remains a major concern. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. For Q2 2025, Wall Street analysts expect Circle Internet to report a loss per share of $1.00. Meanwhile, the company's revenue is expected to increase by about 48% year-over-year to $645.7 million. During the earnings call, investors will be watching Circle Internet's revenue growth, updates on USDC adoption, and any new partnerships or regulatory developments. Recent Event Ahead of Q2 On August 6, Corpay Inc. (CPAY) partnered with Circle Internet to integrate the USDC stablecoin into its global payments network. The deal will allow Corpay clients to use USDC for instant funding, on-chain settlement, and cross-border payouts in over 80 countries. Analyst's View Ahead of Q2 Heading into the Q2 print, Robert W. Baird analyst David Koning maintained a Hold rating on the stock with a $210 price target. He noted that the company expects revenue of $640–$650 million, close to the Street's $646 million forecast, while gross profit is expected to come in only slightly above consensus. Koning believes that Circle faces strong competition in the stablecoin market from both fintechs and traditional banks launching rival products. He also pointed to regulatory uncertainties and interest rate risks that could limit the company's long-term growth. Compass Point analyst Ed Engel downgraded Circle Internet stock to Sell from Hold and lowered the price target from $205 to $130 per share, citing various reasons, including rising competition and elevated valuation. Options Traders Anticipate a Large Move Using TipRanks' Options tool, we can see what options traders are expecting from the stock immediately after its earnings report. The expected earnings move is determined by calculating the at-the-money straddle of the options closest to expiration after the earnings announcement. If this sounds complicated, don't worry; the Options tool does this for you. Indeed, it currently says that options traders are expecting a 10.66% move in either direction. What Is the Target Price of CRCL Stock? Currently, Wall Street is cautious about Circle Internet stock, with a Hold consensus rating based on five Buys, five Holds, and four Sell recommendations. The average CRCL stock price target of $181.50 indicates a possible upside of 14.13% from current levels.
Business Upturn
01-08-2025
- Business Upturn
NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement
LANGHORNE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) — NEXGEL, Inc. ('NEXGEL' or the 'Company') (NASDAQ: 'NXGL'), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 413,044 shares of its common stock (the 'Shares') at $2.30 a share. In a concurrent private placement, NEXGEL also agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 206,522 shares of common stock (the 'Unregistered Warrants'). The Unregistered Warrants will have an exercise price of $4.25 per share and are exercisable immediately upon issuance with a term of five years from the date of issuance. Adam Levy, CEO of NEXGEL, commented, 'This financing, combined with our current cash position, and the recent $1 million non-dilutive advance from STADA, significantly strengthens our balance sheet and provides sufficient additional working capital as we enter a period of anticipated high growth for the second half of the year. We appreciate the continued support from our loyal investors for supporting NEXGEL during this critical period in our history.' Alere Financial Partners, LLC, a division of Cova Capital Partners, LLC acted as the exclusive placement agent for the offering. The Shares offered in the registered direct offering (but excluding the Unregistered Warrants to be issued in the concurrent private placement and the shares of common stock underlying the Unregistered Warrants) are being offered pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-264282) previously filed with the U.S. Securities and Exchange Commission (the 'SEC') under the Securities Act of 1933, as amended, which was declared effective by the SEC on June 7, 2023. A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at Electronic copies of the prospectus supplement may be obtained, when available, from Cova Capital Partners LLC, 6851 Jericho Turnpike, Suite 205, Syosset, New York 11791, or by telephone at (866) 772-8081. The Unregistered Warrants are being offered in the concurrent private placement pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the 'Securities Act'), provided in Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying such Unregistered Warrants, have not been registered under the Securities Act or applicable state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About NEXGEL, Inc. NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies. Forward-Looking Statement This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act') (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words 'believe,' 'anticipate,' 'estimate,' 'expect,' 'intend,' 'plan,' 'project,' 'prospects,' 'outlook,' and similar words or expressions, or future or conditional verbs, such as 'will,' 'should,' 'would,' 'may,' and 'could,' are generally forward-looking in nature and not historical facts, including, without limitation, our anticipated high growth for the second half of the year. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under 'Risk Factors' therein, which the Company filed with the SEC and which may be viewed at Investor Contact:Valter Pinto, Managing DirectorKCSA Strategic Communications212.896.1254 [email protected]
